Methotrexate Versus Triamcinilone Acetonide in Treatment of Recalcitrant Alopecia Areata
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Alopecia areata is the second most common cause of hair loss following androgenic alopecia.
It is affecting 2% of global population with an increasing prevalence. Briefly, it is a
chronic, immunomediated disease characterized by acute onset of non-scarring hair loss
ranging from small circumscribed patchy areas on the scalp to complete scalp and body hair
loss. Until recently our understanding of the pathophysiology of alopecia areata is scarce,
despite being so common.
Methotrexate is an immunosuppressant drug that has been widely used for a range of
inflammatory and immune-mediated skin disorders.
Methotrexate has been recently proven to inhibit Jak/STAT Pathway. Triamcinolone acetonide as
another type of treatment of alopecia areata either intralesionally or topically remains the
first line of treatment.